Gene Therapy for Hemophilia: Progress and Setbacks
As the FDA delayed the approval of the world’s first gene therapy for hemophilia A, companies forged ahead with phase III trials to gather longer-term patient data.
On December 23, 2019, California-based BioMarin Pharmaceutical announced...
Online Exclusives
Emmanuelle Charpentier and Jennifer Doudna Awarded Nobel Prize for CRISPR
The 2020 Nobel Prize in Chemistry was awarded to microbiologist Emmanuelle Charpentier, PhD, and biochemist Jennifer A. Doudna, PhD, for their 2012 discovery of...
California Governor Passes Legislation for State-Sponsored Generic Drugs
California Governor Gavin Newsom recently signed bill SB 852, allowing the creation of a state-sponsored generic drug label, Cal-Rx, through which the state can...
News
From the Blood Journals
Sequential Pembrolizumab and Chemotherapy Results in Excellent Responses in Newly Diagnosed...
A brief course of pembrolizumab monotherapy followed by AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) was associated with reductions in metabolic tumor volume and prolonged...
Is Post-Discharge VTE Prophylaxis Necessary for Patients With COVID-19?
In hospitalized patients with COVID-19, the risk of venous thromboembolism (VTE) following discharge was not significantly greater compared with the VTE risk in patients...
Multimedia
Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia
Treatment with zanubrutinib resulted in a higher combined complete response and very good partial response rate than therapy with ibrutinib in patients with Waldenström...
John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma
Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III...
Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma
Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...
Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma
Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...
On Location
Investigating Tyrosine Kinase Inhibitors for ITP
In two presentations presented at EHA25 Virtual, the 25th European Hematology Association Annual Congress, investigators...
ADAMTS13 Activity Levels Predict iTTP Recurrence
A study presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress...
Studies Confirm Long-Term Benefit of Gene Therapy for Hemophilia A
In two studies presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual...
Is It Time for a Paradigm Shift for CAPS Treatment?
Newer treatment approaches that incorporate monoclonal antibodies reduce the mortality risk in patients with catastrophic...
Late-Breaking Abstracts Address Thrombosis and COVID-19
A growing body of clinical evidence indicates that COVID-19 infection predisposes patients to arterial and...
Extended Half-Life Factor VIII Fusion Protein Effective in Previously Untreated Hemophilia A
The use of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) appeared to be...
Latest Headlines
ASH Directions
Diversity, Equity, and Inclusion in Hematology, and more
Diversity, Equity, and Inclusion in Hematology
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and...
ASH Publishes New Clinical Practice Guidelines on AML in Older Adults, and more
ASH Publishes New Clinical Practice Guidelines on AML in Older Adults
The American Society of Hematology (ASH) is pleased to announce the release of...
NCI Partners with Cancer Research UK, JADPRO Appoints Beth Faiman as Editor-in-Chief, and more
Fred Hutchinson Researchers Receive $3.5-Million Grant for Inherited Blood Disorder Treatment
Hans-Peter Kiem, MD, PhD, and Roland Walter, MD, PhD, from the Fred Hutchinson Cancer...
Remembering Edward Henderson, MD, and more
Remembering Edward Henderson, MD (1932 – 2020)
Hematologist Edward Henderson, MD, passed away on June 25, 2020, at the age of 87.Dr. Henderson spent 12...
Charles L. Sawyers Elected AACR President, Young Investigators Receive More Than $1 Million From...
Charles L. Sawyers Elected 2020-21 AACR President
The Fellows of the American Association for Cancer Research (AACR) announced Charles L. Sawyers, MD, as the AACR...
Gene Therapy for Hemophilia: Progress and Setbacks
As the FDA delayed the approval of the world’s first gene therapy for hemophilia A, companies forged ahead with phase III trials to gather...
New Rules of the Road in TTP Management
In July 2020, the International Society on Thrombosis and Haemostasis (ISTH) issued its first-ever guidelines for the treatment of thrombotic thrombocytopenic purpura (TTP), helping...
Racism Persists in Medicine, Including Hematology
Medicine is not exempt from the explicit and implicit racism seen in other parts of American life.
When Deirdra Terrell, PhD, MPH, started attending...